U.S-China Trade War Heats Up; Should Health Sector Start Worrying?
Executive Summary
As US prepares new tariffs, industry tries to to stay optimistic about business prospects in China.
You may also be interested in...
Industry Urged To Watch And Wait For US/China Tariff War To Blow Over
Don’t do anything rash to avoid US tariffs on drug products, ingredients and supplies from China, consultants advise. It would be better to just wait to see if the tariff war blows over.
Generics, OTC AND API Groups Object To Proposed US Tariffs On Goods From China
AAM, CHPA, SOCMA and BPTF agree that proposed 25% tariffs on pharmaceuticals and APIs from China is a bad idea, unless perhaps it’s just a negotiating ploy.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.